Infections caused by nontuberculous mycobacteria (NTM) appear to be emerging globally, but the definitive reasons for this are unclear. Advances in diagnostic technologies have led to the identification of \>160 species of *Mycobacterium*, including several human pathogens. *M. riyadhense* is a slow-growing NTM identified as a cause of pulmonary and extrapulmonary illnesses in humans from Riyadh, Saudi Arabia ([@R1],[@R2]). At least 8 clinical cases have been reported from France, Bahrain, Saudi Arabia, and South Korea, with 5 of the 8 cases in Saudi Arabia ([@R1]--[@R6]) ([Table](#T1){ref-type="table"}). *M. riyadhense* can be misidentified by commercially available line probe assays as *M. tuberculosis* complex, mostly because of confusing banding patterns ([@R1]). A recent nationwide study of NTM prevalence in Saudi Arabia showed no suspected cases of *M. riyadhense*, which could be due to limiting the screening to line probe assays ([@R7]).

###### Summary of all reported *Mycobacterium riyadhense* infections in Saudi Arabia and other countries\*

  **Case**               **Age, y/sex**   **Nationality**   **City**   **Region/ country**     **Specimen**                        **Smear/ culture results**   **Clinical relevance†**   **Treatment†**            **Treatment outcome**
  ---------------------- ---------------- ----------------- ---------- ----------------------- ----------------------------------- ---------------------------- ------------------------- ------------------------- -----------------------
  **This study**                                                                                                                                                                                                    
  **1**                  25/M             Saudi             Dammam     Eastern/ Saudi Arabia   Sputum                              ++/+                         Yes                       CLR/INH/RFP               Cured
  **2**                  55/M             Saudi             Riyadh     Central/ Saudi Arabia   BAL                                 --/+                         Yes                       INH/RFP/EMB/PZA           Cured
  **3**                  39/F             Non-Saudi         Riyadh     Central/ Saudi Arabia   Sputum                              +/+                          Yes                       INH/RFP/EMB/PZA           Cured
  **4**                  77/M             Saudi             Riyadh     Central/ Saudi Arabia   Tracheal aspirate                   +/+                          Yes                       INH/RFP                   Cured
  **5**                  57/M             Saudi             Riyadh     Central/ Saudi Arabia   Lymph node                          --/+                         Yes                       INH/RFP/CLR               Cured
  **6**                  82/M             Saudi             Riyadh     Central/ Saudi Arabia   BAL                                 --/+                         Yes                       CLR/INH/RFP               Cured
  **7**                  18/M             Saudi             Riyadh     Central/ Saudi Arabia   Gastric aspirate                    +/+                          Yes                       INH/RFP/EMB/PZA           Cured
  **8**                  32/M             Non-Saudi         Riyadh     Central/ Saudi Arabia   Endotracheal aspirate               --/+                         Yes                       CLR/INH/RFP               Cured
  **9**                  61/M             Saudi             Riyadh     Central/ Saudi Arabia   Sputum                              +/+                          Yes                       INH/RFP                   NA
  **10**                 8/M              Saudi             Riyadh     Central/ Saudi Arabia   Lymph node                          --/+                         Yes                       CLR/INH/RFP               Cured
  **11**                 82/M             Saudi             Dammam     Eastern/ Saudi Arabia   Sputum                              +/+                          No                        INH/RFP                   Died
  **12**                 28/M             Saudi             Riyadh     Central/ Saudi Arabia   Lymph node                          --/+                         Yes                       INH/RFP                   Cured
  **Previous reports**                                                                                                                                                                                              
  **(**[@R1]**)**        19/M             Saudi             Riyadh     Central/ Saudi Arabia   Bone infection in maxillary sinus   --/+                         Yes                       INH/RIF/EMB/PZA           Cured
  **(**[@R2]**)**        38/F             South Korea       NA         South Korea             Sputum                              +/+                          Yes                       INH/RIF/EMB/PZA           Cured
  **(**[@R3]**)**        39/F             France            Toulon     France                  Sputum                              +/+                          Yes                       INH/RIF/EMB/PZA           Cured
  **(**[@R4]**)**        43/M             Bahrain           Awali      Bahrain                 Sputum                              --/+                         Yes                       INH/RIF/EMB/PZA/CLR/CIP   Cured
  **(**[@R5]**)**        18/F             Saudi             Jeddah     West/ Saudi Arabia      Brain with bone                     --/+                         Yes                       INH/RIF/EMB/PZA/MX        Cured
  **(**[@R6]**)**        24/F             Saudi             Riyadh     Central/ Saudi Arabia   Spine                               --/+                         Yes                       INH/RIF/EMB/PZA           Cured
  **(**[@R7]**)**        30/M             Saudi             NA         West/ Saudi Arabia      Sputum + lymph node                 +/+                          Yes                       INH/RIF/EMB/PZA           Cured
  **(**[@R8]**)**        54/M             Saudi             NA         Central/ Saudi Arabia   BAL                                 +/+                          Yes                       INH/RIF/EMB/PZA           Cured

\*BA, bronchoalveolar lavage; NA, not available; +, positive; -, negative. Positive smearing results indicate the presence of acid-fast bacilli (AFB). Wherein, 10--99 AFB identified in 100 fields have been noted with (+), and 100--999 AFB in 100 fields correlates with (++). Positive culturing results highlight the presence of mycobacterial growth. CIP, ciprofloxacin; CLR, clarithromycin; EMB, ethambutol; INH, isoniazid; MX, moxifloxacin; PZA, pyrazinamide; RFP, rifampin.  **†Based on American Thoracic Society guidelines for pulmonary NTM disease/colonization (<https://www.thoracic.org/statements/resources/mtpi/nontuberculous-mycobacterial-diseases.pdf>).**

To explore the presence of *M. riyadhense* in clinical settings in Saudi Arabia, we conducted a prospective study on a nationwide collection of isolates. Suspected NTM isolates reported as *M. tuberculosis complex* or *Mycobacterium* species with nonspecific banding pattern by line probe assays were subjected to different conservative gene sequencing to identify *M. riyadhense.*

During April 2014--September 2015, we collected 458 NTM isolates, with clinical and epidemiological data, from all 9 national referral laboratories in different provinces of Saudi Arabia. We formulated the isolate enrollment strategy to suspect *M. riyadhense* on the basis of previous studies ([@R1],[@R2]). In brief, we conducted primary identification of the isolates using line probe assay-Genotype MTBC (Hain Lifescience, Nehren, Germany). We further tested isolates that showed a nonspecific banding pattern (1,2,3) by using Genotype Mycobacteria CM and AS assays (Hain Lifescience). The Genotype Mycobacteria CM assay showed a specific banding pattern of 1,2,3,10,15,16 (1,2,3,10,16 in previous study) for a group of isolates; AS assay identified these isolates as *Mycobacterium* species. We subjected all isolates to partial sequencing of 16S rRNA, *rpoB* and *hsp65* genes using BigDye Terminator chemistry (Applied Biosystems, Foster City, CA, USA) ([@R8]--[@R10]). We then subjected the assembled sequences of all 3 genes to analysis via BLAST (<https://blast.ncbi.nlm.nih.gov>) and the EzTaxon database. We followed stringent identification criteria, requiring similarity [\>]{.ul}99% between isolate and reference strain for species confirmation.

We identified 14 isolates that fit the inclusion criteria; most were reported from the Central province, Riyadh, in Saudi Arabia, but the reason is unclear. Microbiological analysis showed slow-growing mycobacteria producing rough white colonies on LJ medium within 3--4 weeks of incubation at 37°C. Primary sequencing of the 16S rRNA gene showed 12 cases of *M. riyadhense* had a 99%--100% match with 3 database strains (GenBank accession nos. JF896094, JF896095, and NR044449). On the other hand, *rpoB* and *hsp65* sequences also showed 99%--100% similarity with other sequences (accession nos. EU921671, EU27644.1, JF86095 and NR 04449.1). The other closest species observed during the analysis were *M. alsense*, *M. szulgai*, and *M. angelicum* (98% similarity with 16S rRNA gene sequences); *M. genavens* and *M. simulans* (96% similarity with *hsp65* gene sequences); and *M. lacus*, *M. intracellulare*, and *M. malmoense* (94% similarity with *rpoB* gene sequences). Two isolates that matched inclusion criteria could not be identified as *M. riyadhense*; BLAST analysis showed the closest matching species as *M. lacus* DSM 44577(T), with 89% similarity. Two 16S rRNA gene sequences from this study were deposited in GenBank (accession nos. KX898970 and KX898971).

We identified 12 clinical cases of *M. riyadhense* infection, including pulmonary and extrapulmonary invasive infections, over a period of 18 months. Demographically, Saudi citizens dominated; 11 of 12 case-patients were male, and mean age was 50 years. Geographic distribution of cases showed 10 cases from Riyadh (Central province) and 2 from Dammam (Eastern province). Clinical data revealed 9 cases with pulmonary involvement and 3, including a pediatric case, with lymphadenitis. Of note, 75% of the respiratory cases were clinically relevant according to American Thoracic Society criteria for NTM pulmonary disease. Most patients recovered with isoniazid, rifampin, and ethambutol therapy ([Table](#T1){ref-type="table"}).

The lack of advanced molecular diagnostic tools in clinical laboratories in Saudi Arabia impedes the accurate identification of *M. riyadhense*. Without an accurate diagnosis, treatment is delayed. In this study, most of the patients were treated with standard TB regimens; some of them received clarithromycin, which did not appear to be highly effective ([@R2]). To date, no standard treatment regimen for *M. riyadhense* disease has been developed, likely due to its status as a rare species. In the cases reported here, patients generally responded well to the initial therapies, but drug resistance may challenge the empirical treatment used. A strain resistant to isoniazid is already reported from South Korea ([@R3]). We recommend that clinicians in Saudi Arabia be vigilant to the possible emergence of *M. riyadhense* as a more common pathogen.
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